Takeda news

Osaka, Japan, November 18, 2009 - Takeda Pharmaceutical Company Limited (“Takeda”) announced that TAK-438, which is the drug for acid-related diseases, has entered into Phase II clinical trials for the treatment of patients with reflux esophagitis in Japan.

Osaka, Japan, November 18, 2009 - Takeda Pharmaceutical Company Limited (“Takeda”) announced that it has decided to start the Takeda Well-Being Program 2009 - "Giving Children in Long-term Treatment the Energy to Live" (hereinafter referred to as the "Program").

November 13, 2009, Osaka, Japan – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today that it has received the honor of being selected for the Carbon Disclosure Leadership Index (CDLI) 2009 as one of the companies in Japan which have taken the most advanced approaches to emissions disclosure.

Osaka, Japan, October 23, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today that it has received the Good Design Award 2009[*1] from the Japan Industrial Design Promotion Organization for the blister card packaging for Benet® 17.5 mg tablets, which is indicated for the treatment of osteoporosis.

Osaka, Japan, October 20, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today its principal sponsorship of the inaugural Yokohama Women's Marathon, which will be held on Sunday, November 15, 2009.

Osaka, Japan, October 1, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries – Takeda Pharmaceuticals Mexico, S.A.

Osaka and Tokyo, Japan, October 1, 2009 --- Takeda Pharmaceutical Company Limited (Osaka, President: Yasuchika Hasegawa), AstraZeneca K.K. (Osaka, President and CEO: Masahiro Kato), Mitsubishi Tanabe Pharma Corporation (Osaka; President and CEO: Michihiro Tsuchiya), and Eisai Co., Ltd.